

					
						November 17, 2017 - By Ellis Scott
Among 15 analysts covering GlaxoSmithKline (NYSE:GSK), 6 have Buy rating, 1 Sell and 8 Hold. Therefore 40% are positive. GlaxoSmithKline had 23 analyst reports since September 8, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Monday, December 7 by Argus Research. The firm earned “Buy” rating on Thursday, July 14 by Jefferies. The company was maintained on Friday, August 12 by Argus Research. JP Morgan maintained the stock with “Neutral” rating in Wednesday, April 26 report. The stock of GlaxoSmithKline plc (ADR) (NYSE:GSK) earned “Hold” rating by Cantor Fitzgerald on Friday, February 26. The firm has “Neutral” rating by Credit Suisse given on Tuesday, October 20. On Thursday, October 20 the stock rating was initiated by Investec with “Buy”. The stock has “Neutral” rating by Bank of America on Tuesday, September 8. Bank of America downgraded GlaxoSmithKline plc (ADR) (NYSE:GSK) on Thursday, October 26 to “Hold” rating. On Wednesday, September 14 the stock rating was downgraded by BNP Paribas to “Underperform”. See GlaxoSmithKline plc (ADR) (NYSE:GSK) latest ratings:26/10/2017 Broker: Bank of America Rating: Hold Downgrade08/09/2017 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Underweight Downgrade05/07/2017 Broker: Citigroup Old Rating: Buy New Rating: Neutral Downgrade16/06/2017 Broker: J P Morgan Chase Co Rating: Neutral Maintain26/05/2017 Broker: Berenberg Old Rating: Hold New Rating: Buy UpgradeLazard Asset Management Llc increased Tarena Intl (TEDU) stake by 8.87% reported in 2017Q2 SEC filing. Lazard Asset Management Llc acquired 43,336 shares as Tarena Intl (TEDU)’s stock rose 21.17%. The Lazard Asset Management Llc holds 531,800 shares with $9.52M value, up from 488,464 last quarter. Tarena Intl now has $874.00 million valuation. It closed at $15.22 lastly. It is down 81.27% since November 17, 2016 and is uptrending. It has outperformed by 64.57% the S&P500.Lazard Asset Management Llc decreased Priceline.Com (NASDAQ:PCLN) stake by 576 shares to 29 valued at $54,000 in 2017Q2. It also reduced Akamai Tech (NASDAQ:AKAM) stake by 153,512 shares and now owns 70,351 shares. Us Bancorp (NYSE:USB) was reduced too. Among 5 analysts covering Tarena International (NASDAQ:TEDU), 3 have Buy rating, 1 Sell and 1 Hold. Therefore 60% are positive. Tarena International had 10 analyst reports since August 19, 2015 according to SRatingsIntel. The stock of Tarena International Inc(ADR) (NASDAQ:TEDU) earned “Sell” rating by TheStreet on Saturday, September 5. The firm earned “Outperform” rating on Monday, February 22 by Credit Suisse. The firm earned “Hold” rating on Tuesday, August 22 by Nomura. Credit Suisse downgraded the shares of TEDU in report on Thursday, January 14 to “Neutral” rating. The stock of Tarena International Inc(ADR) (NASDAQ:TEDU) earned “Buy” rating by Jefferies on Sunday, August 27.GlaxoSmithKline plc is a global healthcare company. The company has market cap of $85.37 billion. The Firm operates through three divisions: Pharmaceuticals, Vaccines and Consumer Healthcare. It has a 28.07 P/E ratio. The Firm focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus /infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. About 82,327 shares traded. GlaxoSmithKline plc (ADR) (NYSE:GSK) has risen 4.26% since November 17, 2016 and is uptrending. It has underperformed by 12.44% the S&P500.Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.